GlyNAC (Glycine + N-Acetylcysteine)

GlyNAC is not a single molecule but a deliberate pairing of two amino acids, glycine and N-acetylcysteine, designed to solve a specific biochemical problem in aging: the decline of glutathione. Glutathione is the most abundant antioxidant made inside human cells, a small tripeptide assembled from glutamate, cysteine, and glycine, and it is central to detoxifying reactive oxygen species, maintaining protein thiols in their reduced state, and protecting mitochondria. The concept behind GlyNAC emerged from stable-isotope work at Baylor College of Medicine showing that older adults do not lose glutathione because they destroy it faster, but because they synthesize it far more slowly, and that the slowdown traces to low availability of two of its three amino acid components at the same time. Supplying cysteine through the stable N-acetyl form of the amino acid, together with supplemental glycine, restarts synthesis and restores the glutathione pool to concentrations seen in young adults.

The reason a combination outperforms either amino acid alone lies in the structure of the synthesis pathway. Glutathione is built in two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine, then glutathione synthetase adds glycine. Cysteine is normally the limiting substrate for the first step, and N-acetylcysteine is an efficient way to raise intracellular cysteine because free cysteine itself is unstable, prone to oxidation, and irritating to the gut, whereas the acetylated form is absorbed and then deacetylated inside cells to release cysteine where it is needed. Glycine becomes the second constraint. Although the body can make glycine, the total daily demand for glycine across collagen synthesis, creatine production, heme synthesis, and one-carbon metabolism appears to exceed endogenous production, leaving a chronic shortfall that limits the final step of glutathione assembly. By providing both cysteine and glycine, GlyNAC removes both bottlenecks at once, which single-precursor strategies do not.

Restoring glutathione does more than mop up free radicals. Glutathione is a required cofactor for the glutathione peroxidase enzymes that neutralize hydrogen peroxide and membrane lipid hydroperoxides, and it maintains the mitochondrial redox environment on which fatty-acid oxidation and efficient energy production depend. Experiments in aged mice and glutathione-deficient older humans showed that when glutathione falls, mitochondria burn fat less efficiently and insulin resistance develops, and that restoring glutathione reverses both defects. This reframes glutathione from a passive scavenger to an active regulator of metabolism, and it explains why correcting the deficiency with GlyNAC influences such a broad set of outcomes, from insulin sensitivity and inflammation to endothelial function and physical performance, rather than a single narrow endpoint.

The clinical evidence for GlyNAC is concentrated in a series of trials from a single research group and is best described as promising but early. An open-label pilot in older adults, a placebo-controlled randomized trial against an isonitrogenous alanine control, and an open-label trial in aging HIV patients each showed correction of glutathione deficiency and oxidative stress alongside improvements in mitochondrial function, inflammation, insulin resistance, endothelial function, strength, gait speed, and cognition. A mouse study reported a 24 percent extension of lifespan. The most important caveats are that the human trials are small, most originate from one laboratory, the benefits reverse when supplementation stops, and the lifespan finding is confined to rodents. GlyNAC targets a documented and measurable deficiency, which is a stronger scientific footing than many supplements enjoy, but larger and independent trials are needed to establish how much of the early promise translates into durable human benefit.

Mechanism of Action

Correcting the Glutathione Synthesis Bottleneck

Glutathione is synthesized in two ATP-dependent enzymatic steps, and understanding those steps explains why GlyNAC works where single amino acids do not. In the first and committed step, glutamate-cysteine ligase joins glutamate to cysteine to form the dipeptide gamma-glutamylcysteine; in the second, glutathione synthetase adds glycine to complete the tripeptide. Cysteine is the substrate normally in shortest supply, which makes the first step rate-limiting under most conditions. Stable-isotope studies in aging humans revealed that older adults do not degrade glutathione faster than young adults but synthesize it far more slowly, and that the slowdown coincides with reduced intracellular concentrations of both cysteine and glycine. GlyNAC addresses this directly by delivering cysteine through its stable N-acetyl carrier and supplying glycine to satisfy the second step. When both amino acids are provided, the synthesis rate recovers, and red-blood-cell glutathione in deficient older adults returns to concentrations comparable to young controls within one to two weeks.

N-Acetylcysteine as a Cysteine Delivery System

N-acetylcysteine is used rather than cysteine itself because free cysteine is a poor oral supplement. Cysteine oxidizes readily to cystine, can irritate the gastrointestinal tract, and at higher intakes carries the potential for excitotoxic and pro-oxidant effects. Acetylating the amino nitrogen produces a molecule that is chemically stable, survives absorption, and is then deacetylated by intracellular acylases to release free cysteine inside the cell, precisely where glutamate-cysteine ligase can use it. The oral bioavailability of the intact NAC molecule is low, on the order of 4 to 10 percent, but this figure understates its usefulness because the point of NAC is not to circulate intact but to be hydrolyzed to cysteine. The free thiol group of NAC also scavenges some reactive oxygen species directly, but this direct antioxidant contribution is minor compared with its function as a cysteine precursor that feeds glutathione synthesis.

Glycine as the Second Rate-Limiting Substrate

Glycine is often overlooked because it is a nonessential amino acid the body can synthesize, but the daily demand for glycine appears to exceed endogenous production. Glycine is consumed in large quantities for collagen synthesis, where it constitutes roughly a third of the amino acid residues, and it is also required for creatine synthesis, heme production, bile acid conjugation, and one-carbon metabolism. When this total demand outstrips supply, glycine availability becomes a genuine constraint on the final step of glutathione assembly. This is the biochemical rationale for adding glycine to a cysteine-based supplement: NAC alone relieves the first bottleneck but leaves the second in place. By supplying both amino acids, GlyNAC restores flux through the entire pathway, which is why the combination raises glutathione more completely than either component given alone.

Glutathione, Mitochondrial Function, and Fuel Oxidation

Glutathione is not only a cytosolic antioxidant; a dedicated pool resides in mitochondria, where it protects against the superoxide and hydrogen peroxide generated as byproducts of the electron transport chain. When mitochondrial glutathione falls, oxidative damage to mitochondrial proteins, lipids, and DNA accumulates, and fuel oxidation suffers. Experiments in aged mice and glutathione-deficient older humans showed that low glutathione reduces fasted mitochondrial oxidation of nonesterified fatty acids and produces insulin resistance, and that restoring glutathione reverses both defects. The mitochondrial glutathione pool also supports the glutathione peroxidase enzymes GPX1 and GPX4, which neutralize peroxides that would otherwise damage the inner mitochondrial membrane and trigger dysfunction. By replenishing this pool, GlyNAC restores the redox environment mitochondria require to burn fat efficiently and maintain membrane integrity, connecting a redox deficiency to concrete metabolic consequences.

Redox Control of Inflammation

The reduction in inflammation seen with GlyNAC follows from the redox sensitivity of the pathways that drive it. Reactive oxygen species activate the NLRP3 inflammasome, a protein complex that assembles in response to mitochondrial oxidative stress and cleaves pro-IL-1beta and pro-IL-18 into their active inflammatory forms. Oxidative stress also promotes activation of NF-kappaB, a transcription factor that induces TNF-alpha, IL-6, and other pro-inflammatory mediators, and whose signaling is amplified when the cellular thiol buffer is depleted. By restoring glutathione and lowering the reactive oxygen species that prime these pathways, GlyNAC acts upstream of the cytokines rather than blocking any single one, which is consistent with the broad reductions in inflammatory markers reported in the aging and HIV trials.

Epigenetic Modulation

Redox status intersects with the epigenome through several routes, so restoring glutathione has consequences beyond direct radical scavenging. The glutathione and methionine cycles are metabolically linked: cysteine for glutathione can be drawn from homocysteine through the transsulfuration pathway, and the balance between transsulfuration and remethylation influences the availability of S-adenosylmethionine, the universal methyl donor for DNA and histone methyltransferases. By supplying cysteine directly, N-acetylcysteine can spare homocysteine from transsulfuration and shift one-carbon flux, an effect that has been observed to alter global DNA methylation in experimental systems.

Protein S-glutathionylation is a second, more direct epigenetic-adjacent mechanism. Under oxidative conditions, glutathione forms reversible mixed disulfides with reactive cysteine residues on proteins, a modification that regulates the activity of numerous transcription factors and chromatin-associated enzymes. The redox state of the glutathione pool therefore governs whether these regulatory cysteines are oxidized or reduced, tuning the activity of stress-responsive transcriptional programs. Because GlyNAC shifts the ratio of reduced to oxidized glutathione toward the reduced state, it influences this layer of redox-dependent post-translational regulation.

N-acetylcysteine has also been reported to modulate the activity of sirtuins and histone-modifying enzymes indirectly through its effects on cellular redox and NAD-dependent signaling, though the evidence in this area is more preliminary than the well-established substrate role in glutathione synthesis. The mitochondrial deacetylase SIRT3, which activates SOD2 and other antioxidant enzymes by removing acetyl marks, operates within the same mitochondrial redox network that GlyNAC supports, illustrating how the compound’s redox effects and the epigenetic regulation of antioxidant defense are intertwined.

Clinical Evidence

Glutathione Deficiency and Oxidative Stress in Aging

The clearest and most rigorously measured finding is that aging causes a synthesis-driven glutathione deficiency that supplementation reverses. Using deuterated glycine infusions, researchers found that elderly adults had red-blood-cell glutathione concentrations of 1.12 mmol/L compared with 2.08 mmol/L in young adults, with the absolute synthesis rate reduced to roughly a third of the young value. Elderly subjects also had elevated plasma oxidative stress and F2-isoprostanes of 136.3 pg/mL versus 97.7 pg/mL in young controls. After two weeks of cysteine and glycine supplementation, glutathione concentration rose by 94.6 percent, the absolute synthesis rate rose by 230.9 percent, and oxidative stress markers fell to levels indistinguishable from young adults. This isotope-based work is the quantitative backbone of the entire GlyNAC program.

The GlyNAC Older-Adult Trials

Two trials extended the precursor concept to the named GlyNAC combination in older adults. An open-label pilot enrolled eight older adults and eight young adults over a 36-week protocol; older adults were studied at baseline, after 24 weeks of GlyNAC, and after a 12-week withdrawal. GlyNAC corrected intracellular glutathione deficiency, oxidative stress, and mitochondrial dysfunction, and improved inflammation, insulin resistance, endothelial function, genomic damage, gait speed, grip strength, cognition, and body composition. Critically, most benefits declined after the 12-week withdrawal, showing the effects depend on continued intake. A subsequent 16-week randomized trial enrolled 24 older adults assigned to either GlyNAC or an isonitrogenous alanine placebo, plus 12 young adults, and found that GlyNAC and not placebo corrected the same panel of defects and improved physical function. The placebo comparison is important because it controls for the added nitrogen and calories, isolating the effect to the glycine and cysteine themselves.

Mitochondrial Fuel Oxidation and Insulin Resistance

The metabolic effects rest on a mechanistic chain established before the GlyNAC trials. Work in aged mice and glutathione-deficient older humans showed that glutathione deficiency impairs fasted mitochondrial oxidation of nonesterified fatty acids and drives insulin resistance, and that restoring glutathione reverses both. A follow-up trial in older HIV patients found that raising glutathione with cysteine and glycine improved mitochondrial fuel oxidation, insulin sensitivity, and body composition. These findings frame the insulin-sensitizing effects of GlyNAC in older adults not as an incidental benefit but as a predictable downstream consequence of restoring mitochondrial redox balance.

HIV and Accelerated Aging

People aging with HIV experience elevated oxidative stress, mitochondrial dysfunction, and inflammation resembling premature aging, making them an informative test population. An open-label GlyNAC trial in aging HIV patients reported improvements across glutathione status, oxidative stress, mitochondrial dysfunction, inflammation, endothelial dysfunction, insulin resistance, genotoxicity, strength, and cognition. That the same intervention produces a similar pattern of benefit in aging and in HIV-associated accelerated aging supports the interpretation that GlyNAC targets a shared underlying redox deficiency rather than a single disease process.

Lifespan Extension in Mice

The most striking preclinical result is a lifespan effect. In C57BL/6J mice, GlyNAC supplementation extended length of life by 24 percent compared with placebo while correcting glutathione deficiency, oxidative stress, mitochondrial dysfunction, defective mitophagy, abnormal nutrient sensing, and genomic damage in heart, liver, and kidney. This is proof-of-concept that correcting the redox and mitochondrial defects of aging can lengthen lifespan in a mammal. It must be read with appropriate caution: the finding is confined to one mouse strain in one study, and no human trial has tested survival or hard clinical endpoints, only markers of aging over months.

GlyNAC versus NAC or Glutathione Alone

The rationale for the combination is best appreciated by contrast with the alternatives. Oral glutathione is intuitively appealing but poorly suited to the task, because most of an oral dose is broken down by intestinal and hepatic enzymes before it can raise intracellular concentrations meaningfully; some sustained-dosing studies show modest increases in body stores, but the approach does not reliably restore the deficit that drives aging-related oxidative stress. N-acetylcysteine alone supplies cysteine and relieves the first synthesis bottleneck, and it has a long clinical history as a mucolytic and as the antidote for acetaminophen overdose, but it does not address the glycine shortfall that limits the final step. Glycine alone relieves the second bottleneck but not the first. The central thesis of the GlyNAC work is that both amino acids must be supplied together to fully restore synthesis, and the trials were designed to test precisely that combination. This makes GlyNAC a more complete strategy than either precursor alone, while acknowledging that head-to-head trials directly comparing GlyNAC with NAC alone or glycine alone in the same population are still limited.

Dosing Guidance

The published trials used glycine and N-acetylcysteine each at 100 mg per kilogram of body weight per day, which works out to approximately 7 grams of glycine plus 7 grams of NAC daily for a 70 kilogram adult, generally split into divided doses and titrated up over the first week to limit gastrointestinal upset. Trial durations ran from 16 to 24 weeks for the main outcomes, with intracellular glutathione recovering within one to two weeks and functional endpoints such as strength and gait speed improving over the longer window. Many commercial GlyNAC products deliver considerably less than the trial dose, so anyone attempting to reproduce the studied intake should compare product labels against the 100 mg per kg per day figure. Because the benefits reversed within 12 weeks of stopping in the pilot trial, GlyNAC is best understood as ongoing correction of a deficiency rather than a short course, and the amino acids are taken with food to reduce the sulfurous taste and gastrointestinal effects associated with NAC.